Does Remotely Delivered Pilates Influence Physical and Psychological Outcomes in Individuals With Multiple Sclerosis?

Official Summary

Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS. Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS. Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS. Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS. Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Study Design

• Study Type: INTERVENTIONAL
• Allocation: RANDOMIZED
• Model: PARALLEL
• Masking: SINGLE
• Enrollment: 50 participants

Interventions

• BEHAVIORAL: Pilates — REMOTLY PILATES EXERCISE

Primary Outcomes

• Change from baseline in walking endurance (Six-Minute Walk Test distance) (Baseline and 16 weeks (end of treatment))
• Change from baseline in walking speed (Timed 25-Foot Walk) (Baseline and 16 weeks (end of treatment))
• Change from baseline in balance (Berg Balance Scale) (Baseline and 16 weeks (end of treatment))
• Change from baseline in fatigue (Fatigue Severity Scale) (Baseline and 16 weeks (end of treatment))
• Change from baseline in pain (Short-form McGill Pain Questionnaire) (Baseline and 16 weeks (end of treatment))

Secondary Outcomes

• Change from baseline in cognitive processing speed (Symbol Digit Modalities Test) (Baseline and 16 weeks (end of treatment))
• Change from baseline in verbal learning and memory (California Verbal Learning Test-II) (Baseline and 16 weeks (end of treatment))
• Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised) (Baseline and 16 weeks (end of treatment))
• Change from baseline in depression symptoms (Baseline and 16 weeks (end of treatment))
• Change from baseline in anxiety symptoms (Baseline and 16 weeks (end of treatment))

More Multiple Sclerosis Trials

View all Multiple Sclerosis clinical trials